ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock

Myriam Alvarez3.23K FollowersFollow5ShareSavePlay(11min)Comment(1)SummarySPRY’s main product is Neffy, which is a needle-free epinephrine spray. Its sales are ramping quickly, and Q3 2025 sales hit $31.3 million.My core thesis is that Neffy’s more convenient delivery mechanism will resonate with patients far better than injections.Also, a convenient nasal spray is a much simpler administration method that should reduce user error and unlock diagnosed-but-untreated anaphylaxis demographics.SPRY also has international approvals and partners (Europe, UK, Japan, China, Australia), which help diversify its commercialization risk beyond the US.In my view, CSU (currently in Phase 2b) could open another valuable franchise as well. So, on balance, I feel SPRY now offers a compelling “Buy” opportunity. dragana991/iStock via Getty Images ARS Pharmaceuticals, Inc. (SPRY) is a commercial-stage biopharmaceutical company that produces Neffy for type I allergic reactions, including anaphylaxis. This asset is a needle-free intranasal epinephrine dose, which offers a more convenient route of administration than theThis article was written byMyriam Alvarez3.23K FollowersFollowMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business Management from Universidad Andina Simon Bolivar, Quito, Ecuador, and the Ph.D. degree in computer applications from the University of Alicante, Spain.Disclosure: I collaborate professionally with Edgar Torres H, who is also an author on Seeking Alpha. Our analyses are conducted independently, and we adhere to Seeking Alpha's Shared Association Guidelines.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.